Expression of the SART3 tumor rejection antigen in renal cell carcinoma

Journal of Urology

Volumn 164, Issue 6, 2000, Pages 2090-2095

  Kawagoe, Nobutoshi ^a,b,c   Shintaku, Ichiro ^a,b,c   Yutani, Shigeru ^a,b,c   Etoh, Hiroshi ^a,b,c   Matuoka, Kei ^a,b,c   Noda, Shinshi ^a,b,c   Itoh, Kyogo ^a,b,c  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KOBE UNIVERSITY   (Japan)

Author keywords

Cancer vaccines; Carcinoma, renal cell; Immunotherapy; T lymphocytes, cytotoxic

Indexed keywords

HLA ANTIGEN CLASS 1; PEPTIDE DERIVATIVE; SART3 ANTIGEN; TUMOR REJECTION ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MONONUCLEAR CELL; PRIORITY JOURNAL; TUMOR REJECTION;

EID: 0033767428     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)66975-3     Document Type: Article

References (37)

1. Renal cell carcinoma-specific lysis by cytotoxic T lymphocyte clones isolated from peripheral blood lymphocytes and tumor-infiltrating lymphocytes
2. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin 2 or high-dose interleukin 2 alone
3. Biological response modifiers: The new immunotherapy
4. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A: An active outpatient regimen in metastatic renal carcinoma
5. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokin-activated killer cells for the treatment of patients with advanced cancer
6. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
7. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
8. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
9. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen
10. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor
11. Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage
12. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltration T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles
13. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
14. The natural history of metastatic renal cell carcinoma: A computer analysis
15. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma
16. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma
17. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: Sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC
18. Tumor-specific lysis of human renal cell carcinoma by tumor-infiltrating lymphocytes
19. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes
20. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted Cytotoxic T Lymphocytes in cancer patients
21. Expression of MAGE gene family by human head and neck squamous cell carcinoma
22. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes
23. Human renal cell carcinoma cells are able to activate natural killer cells
24. Clonal analysis of lymphocytes from tumor, peripheral blood, and nontumorous kidney in primary renal cell carcinoma
25. Identification of a SART1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes
26. Identification and characterization of multiple HLA A24-restricted HIV-1ct1 epitopes: Strong epitopes are derived from v regions of HIV-1
27. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes
28. Role of strong anchor residues in the effective binding of 10-mer and 11-mer peptides to HLA-A2402 molecules
29. Establishment and characterization of human renal cell and normal kidney cell lines
30. Higher susceptibility of erythropoietin-producing renal cell carcinomas to lysis by lymphokine-activated killer cells
31. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity
32. Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt-Koyanagi-Harada disease
33. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE3
34. Selective regulation of apoptosis: The cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against grazyme B-mediated apoptosis without perturbing the Fas cell death pathway
35. A new family of 10 murine ovalbumin serpins induces two homologs of proteinase inhibitor 8 and two homologs of the granzyme B inhibitor (proteinase inhibitor 9)
36. Identification of SART3-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with different HLA-A2 subtypes